Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Does Bismuth Subnitrate Normalize Intestinal Conditions in Patients With Chronic Diarrhea?

Does Bismuth Subnitrate Normalize Intestinal Conditions in Patients With Chronic Diarrhea? Abstract To the Editor. —Bismuth-containing drugs, such as bismuth subsalicylate and subnitrate, have been widely employed as antidiarrheal agents in symptomatic therapy for traveler's diarrhea.1 Graham et al1 reported that bismuth subsalicylate prevents diarrhea by reducing the number or multiplication of enterotoxigenic Escherichia coli, which causes most cases of traveler's diarrhea. However, it has been demonstrated that there are risks of encephalopathy from bismuth subsalicylate and of hypercalcemia (milk-alkali syndrome) from bismuth subsalicylate tablets containing a large amount of calcium carbonate.2,3 I recently encountered a 72-year-old woman in Japan who developed a paralytic ileuslike syndrome following treatment with bismuth subnitrate for chronic diarrhea due to antitubercular agents. Report of a Case. —The patient was admitted because of hemosputum of two months' duration, a positive sputum culture of Mycobacterium tuberculosis, and chest roentgenogram revealing infiltrative shadows over the right middle lobe. The patient was treated with antitubercular drugs including References 1. Graham DY, Estes MK, Gentry LO: Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli—induced diarrhea in volunteers. Gastroenterology 1983;85:1017-1022. 2. Hasking GJ, Duggan JM: Encephalopathy from bismuth subsalicylate. Med J Aust 1982; 69:167. 3. Levine RA: Risk of hypercalcemia from prophylaxis of traveler's diarrhea. JAMA 1983; 249:1151-1152.Crossref 4. Steffen R, DuPont HL, Heusser R, et al: Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986;29:625-627.Crossref 5. Goldenberg MM, Honkomp LJ, Burrous SE, et al: Protective effect of Pepto-Bismol liquid on the gastric mucosa of rats. Gastroenterology 1975;69:636-640. 6. Mennie AT, Dalley VM, Dinneen LC, et al: Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet 1975;2:942-943.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Does Bismuth Subnitrate Normalize Intestinal Conditions in Patients With Chronic Diarrhea?

Umeki, Shigenobu
Archives of Internal Medicine , Volume 148 (9) – Sep 1, 1988
Download PDF
1 page

Does Bismuth Subnitrate Normalize Intestinal Conditions in Patients With Chronic Diarrhea?

Abstract

Abstract To the Editor. —Bismuth-containing drugs, such as bismuth subsalicylate and subnitrate, have been widely employed as antidiarrheal agents in symptomatic therapy for traveler's diarrhea.1 Graham et al1 reported that bismuth subsalicylate prevents diarrhea by reducing the number or multiplication of enterotoxigenic Escherichia coli, which causes most cases of traveler's diarrhea. However, it has been demonstrated that there are risks of encephalopathy from bismuth...
Loading next page...
 
/lp/american-medical-association/does-bismuth-subnitrate-normalize-intestinal-conditions-in-patients-FudpFy3VSM

References (6)

Publisher
American Medical Association
Copyright
Copyright © 1988 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1988.00380090129030
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —Bismuth-containing drugs, such as bismuth subsalicylate and subnitrate, have been widely employed as antidiarrheal agents in symptomatic therapy for traveler's diarrhea.1 Graham et al1 reported that bismuth subsalicylate prevents diarrhea by reducing the number or multiplication of enterotoxigenic Escherichia coli, which causes most cases of traveler's diarrhea. However, it has been demonstrated that there are risks of encephalopathy from bismuth subsalicylate and of hypercalcemia (milk-alkali syndrome) from bismuth subsalicylate tablets containing a large amount of calcium carbonate.2,3 I recently encountered a 72-year-old woman in Japan who developed a paralytic ileuslike syndrome following treatment with bismuth subnitrate for chronic diarrhea due to antitubercular agents. Report of a Case. —The patient was admitted because of hemosputum of two months' duration, a positive sputum culture of Mycobacterium tuberculosis, and chest roentgenogram revealing infiltrative shadows over the right middle lobe. The patient was treated with antitubercular drugs including References 1. Graham DY, Estes MK, Gentry LO: Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli—induced diarrhea in volunteers. Gastroenterology 1983;85:1017-1022. 2. Hasking GJ, Duggan JM: Encephalopathy from bismuth subsalicylate. Med J Aust 1982; 69:167. 3. Levine RA: Risk of hypercalcemia from prophylaxis of traveler's diarrhea. JAMA 1983; 249:1151-1152.Crossref 4. Steffen R, DuPont HL, Heusser R, et al: Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986;29:625-627.Crossref 5. Goldenberg MM, Honkomp LJ, Burrous SE, et al: Protective effect of Pepto-Bismol liquid on the gastric mucosa of rats. Gastroenterology 1975;69:636-640. 6. Mennie AT, Dalley VM, Dinneen LC, et al: Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet 1975;2:942-943.Crossref

Journal

Archives of Internal Medicine – American Medical Association

Published: Sep 1, 1988

There are no references for this article.